MBX Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MBX Biosciences, Inc. on July 9, 2026, reporting events effective July 13, 2026. The filing details significant changes to the Company's executive leadership, including the departure of the Chief Executive Officer and the appointment of new Chief Executive and Chief Financial Officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The Company announced the following material changes to its executive team:
- Departure of CEO: Kent P. Hawryluk is stepping down as Chief Executive Officer and Board member effective July 13, 2026. His departure is not due to any dispute with the Company or its auditors.
- Appointment of CEO: Steven Hoerter, currently the Executive Chairman of the Board, was appointed President and Chief Executive Officer effective July 13, 2026.
- Appointment of CFO: John Smither, currently the Interim Chief Financial Officer, was appointed Chief Financial Officer effective July 13, 2026.
Compensation, Guidance, and Risks
Executive Compensation and Equity Grants:
- Kent P. Hawryluk (Outgoing CEO): Entitled to 12 months of base salary severance, 12 months of COBRA coverage, a cash bonus equal to his target annual bonus, and accelerated vesting of time-based equity awards through August 16, 2027. He will provide strategic advisory services through August 16, 2026.
- Steven Hoerter (New CEO): Base salary of $665,000 with a target annual bonus of 60%. Equity awards include 331,000 stock options and 71,000 RSUs, vesting over four years (25% annually).
- John Smither (New CFO): Base salary of $530,000 with a target annual bonus of 40%. He received a one-time relocation bonus of $150,000. Equity awards include 130,000 stock options and 28,000 RSUs, vesting over four years (25% annually).
Guidance and Outlook: The filing does not contain financial guidance, operational outlook, or management commentary regarding future business performance.
Risks and Contingencies: The filing notes that the separation and employment agreements are subject to customary post-employment obligations, including confidentiality, non-competition, and non-solicitation covenants. Full agreement texts will be filed as exhibits to the Form 10-Q for the quarter ending September 30, 2026.
Key Facts for Investor Verification
- Verify the exact terms of the separation agreement for Kent P. Hawryluk in the upcoming Form 10-Q exhibit.
- Confirm the vesting schedules and exercise prices for the new equity grants to Steven Hoerter and John Smither.
- Monitor the transition period through August 16, 2026, to ensure continuity of operations under the new leadership.
- Review the Company's cash position to assess the impact of the immediate cash severance and relocation bonuses.